MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
SCLX stock logo

SCLX

Scilex Holding Company

$7.44
0.53
 (7.67%)
Exchange:  NASDAQ
Market Cap:  63.551M
Shares Outstanding:  4.031M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – General
   
CEO:  Henry H. Ji
Full Time Employees:  115
Address: 
960 San Antonio Road
Palo Alto
CA
94303
US
Website:  https://www.scilexholding.com
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue46,74356,59030,253
Gross Profit31,06239,90115,031
EBITDA-109,104-66,799-267,681
Operating Income-105,431-83,396-272,304
Net Income-114,331-72,807-358,734

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets101,30992,953364,981
Total Liabilities274,247285,594576,733
Total Stockholders Equity-172,938-192,641-211,752
Total Debt128,46337,95898,146
Cash and Cash Equivalents3,9213,2724,955

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-20,70719,3493,816
Capital Expenditure-3300-133
Free Cash Flow-21,03719,3493,683
Net Income-114,331-72,807-358,734
Net Change in Cash2,545-1,4570

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)1,091,027Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)1,091,027Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)1,091,027Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-926,193.973Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-926,193.973Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-926,193.973Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)138,807.732Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)138,807.732Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)138,807.732Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)3,665,250.645Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)3,665,250.645Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)3,665,250.645Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)12.580Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)12.580Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)12.580Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
1.94
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-0.19
?Enterprise Value
 (TTM)
: 
186.187M  ?EV/FCF
 (TTM)
: 
54.37
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
1.9  ?ROIC
 (TTM)
: 
10.32
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
-0.64
?P/B
 (TTM)
: 
-0.37  ?Current Ratio
 (TTM)
: 
0.08

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
2.39Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates SCLX intrinsic value between $40.95 – $42.00 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate SCLX Intrinsic Value

Common questions about SCLX valuation

Is Scilex Holding Company (SCLX) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Scilex Holding Company (SCLX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is SCLX a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether SCLX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is SCLX’s P/E ratio?

You can see SCLX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for SCLX?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is SCLX a good long-term investment?

Whether SCLX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

SCLX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

7.67
MARKETSnap

Trading Metrics:

Open: 6.77   Previous Close: 6.91
Day Low: 6.77   Day High: 7.76
Year Low: 3.6   Year High: 34.27
Price Avg 50: 8.27   Price Avg 200: 13.93
Volume: 54706   Average Volume: 45270

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Datavault AI Announces Execution of Binding Term Sheet for $120 Million Cash Contribution From Scilex Holding Company to Fund 100-City GPU Expansion of Quantum-Ready SanQtum Platform
27-04-2026 08:45
Datavault AI Announces Execution of Binding Term Sheet for $120 Million Cash Contribution From Scilex Holding Company to Fund 100-City GPU Expansion of Quantum-Ready SanQtum Platform
Scilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April
20-04-2026 09:00
Scilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April
Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets
30-01-2026 09:00
Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets
Scilex (NASDAQ:SCLX) Trading Up 8.8%  – Time to Buy?
23-01-2026 02:44
Scilex (NASDAQ:SCLX) Trading Up 8.8% – Time to Buy?
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
07-01-2026 08:55
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel
02-01-2026 09:00
Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read